Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant DepressionBusiness Wire • 03/18/25
Psychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst SaysBenzinga • 02/27/25
Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business HighlightsBusiness Wire • 02/27/25
Compass Pathways to Participate in TD Cowen 45th Annual Health Care ConferenceBusiness Wire • 02/25/25
Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025Business Wire • 02/18/25
Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences ConferenceBusiness Wire • 02/05/25
RFK Jr's appointment in health could accelerate psychedelic drug development, analysts sayProactive Investors • 11/12/24
Compass Pathways Announces Third Quarter 2024 Financial Results and Business UpdatesBusiness Wire • 10/31/24
Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024Business Wire • 10/24/24
Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry SummitBusiness Wire • 09/23/24